<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00079638</url>
  </required_header>
  <id_info>
    <org_study_id>001-09-03-CR</org_study_id>
    <secondary_id>COMPELL</secondary_id>
    <nct_id>NCT00079638</nct_id>
  </id_info>
  <brief_title>Comparative Efficacy Evaluation of Lipids When Treated With Niaspan &amp; Statin or Other Lipid-Modifying Therapies-COMPELL</brief_title>
  <official_title>Comparative Efficacy Evaluation of Lipid Levels When Treated With Niaspan and Statin or Other Lipid-Modifying Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kos Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kos Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of first-line treatment using&#xD;
      Niaspan (an extended release version of niacin) and statins versus other drugs that lower&#xD;
      lipid levels, in subjects with elevated fat levels in their blood (dyslipidemia). Statins are&#xD;
      a class of medication that is often prescribed to patients who need to lower their&#xD;
      cholesterol levels.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Name of Drugs: Niaspan (niacin extended-release tablets), Lipitor® (atorvastatin), Zocor®&#xD;
      (simvastatin), Zetia™ (ezetimibe), and Crestor® (rosuvastatin)&#xD;
&#xD;
      Study Treatment: Four open-label parallel treatment groups for 12 weeks of observation&#xD;
&#xD;
        -  Niaspan and atorvastatin combination treatment titrated to 2000 mg and 40 mg,&#xD;
           respectively;&#xD;
&#xD;
        -  combination treatment of simvastatin titrated to 40 mg and ezetimibe maintained at 10&#xD;
           mg;&#xD;
&#xD;
        -  rosuvastatin monotherapy treatment titrated to 40 mg; and&#xD;
&#xD;
        -  Niaspan and rosuvastatin combination treatment titrated to 1000 mg and 20 mg,&#xD;
           respectively.&#xD;
&#xD;
      Objective: To evaluate the relative efficacy of first-line therapy using the combination of&#xD;
      Niaspan and atorvastatin versus the combination of simvastatin and ezetimibe versus&#xD;
      rosuvastatin monotherapy versus the combination of Niaspan and rosuvastatin in patients with&#xD;
      dyslipidemia.&#xD;
&#xD;
      Population:&#xD;
&#xD;
        -  Male or female patients 21 years of age or older&#xD;
&#xD;
        -  Patients who are eligible for treatment based upon National Cholesterol Education&#xD;
           Program Adult Treatment Panel III (NCEP-ATP III) recommendations at the end of the&#xD;
           Qualification period;&#xD;
&#xD;
        -  All patients must have mean triglycerides (TG) ≤ 300 mg/dL.&#xD;
&#xD;
      Design: A Phase IV, 12-week, randomized, multi-center, open-label, four-arm, parallel-group&#xD;
      study evaluating the efficacy of Niaspan and statin therapy versus other lipid-modifying&#xD;
      therapies preceded by a four-week washout of any previous lipid-lowering therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date>May 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean percent change in LDL-C from Baseline to Week 12</measure>
  </primary_outcome>
  <enrollment>300</enrollment>
  <condition>Dyslipidemia</condition>
  <condition>Coronary Heart Disease</condition>
  <condition>Atherosclerosis</condition>
  <condition>Stroke</condition>
  <condition>Diabetes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niacin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All of the following criteria must be answered &quot;Yes&quot;:&#xD;
&#xD;
          1. Patient is 21 years of age or older and willing to participate for the duration of the&#xD;
             study;&#xD;
&#xD;
          2. Patient has read, signed, and agreed to the items listed in the informed consent form&#xD;
             and HIPAA authorization form prior to the initiation of any study procedures and/or&#xD;
             discontinuing any medications;&#xD;
&#xD;
          3. Patient is eligible for treatment following the drug washout period based upon the&#xD;
             NCEP ATP III entry criteria and the LDL-C variability ≤ 15%;&#xD;
&#xD;
          4. Patient has mean triglyceride level (TG) ≤ 300 mg/dL;&#xD;
&#xD;
          5. Patient is willing to withdraw from any current anti-dyslipidemic medications or other&#xD;
             prohibited medication for approximately 6 weeks prior to randomization (4 weeks prior&#xD;
             to qualification visits) and for the duration of the study;&#xD;
&#xD;
          6. If the patient is female, the patient must not be pregnant or breast-feeding and not&#xD;
             planning to become pregnant or to breast-feed for the duration of the study. Women of&#xD;
             childbearing potential must commit to using a medically acceptable method of birth&#xD;
             control such as oral contraception, intrauterine device (IUD), or a double-barrier&#xD;
             method of contraception. Women using oral contraception must have done so for at least&#xD;
             3 months prior to randomization, and continue to do so for the duration of the study.&#xD;
             To be considered not of childbearing potential, women must be post-menopausal for at&#xD;
             least 2 years or surgically sterile.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All the following criteria must be answered &quot;No&quot;:&#xD;
&#xD;
          1. Patient has an allergy, hypersensitivity, or intolerance to niacin, simvastatin,&#xD;
             atorvastatin, ezetimibe, rosuvastatin or their derivatives;&#xD;
&#xD;
          2. Patient drinks more than 14 alcoholic drinks per week or has a previous history&#xD;
             (within 12 months of screening) of substance abuse or dependency;&#xD;
&#xD;
          3. Patient has untreated or unsuccessfully treated psychiatric disease;&#xD;
&#xD;
          4. Patient has used an investigational study medication or participated in an&#xD;
             investigational study within 30 days of obtaining qualification labs;&#xD;
&#xD;
          5. Patient has taken a prohibited medication within 4 weeks of obtaining qualification&#xD;
             labs for the study (See section 8.0 - Concomitant Medications);&#xD;
&#xD;
          6. Patient has a history of any of the following:&#xD;
&#xD;
               -  active gallbladder disease within the preceding 12 months (cholecystectomy is&#xD;
                  allowed);&#xD;
&#xD;
               -  pancreatitis;&#xD;
&#xD;
               -  liver disease (e.g., hepatitis B and/or C);&#xD;
&#xD;
               -  persistent uncontrolled or untreated severe hypertension;&#xD;
&#xD;
               -  Type I or Type II diabetes;&#xD;
&#xD;
               -  persistent uncontrolled or untreated hypothyroidism;&#xD;
&#xD;
               -  arterial bleeding;&#xD;
&#xD;
               -  unstable angina;&#xD;
&#xD;
               -  myocardial infarction, coronary artery bypass graft surgery, or angioplasty&#xD;
                  within the preceding 6 months;&#xD;
&#xD;
               -  stroke, transient ischemic attack (TIA), or deep vein thrombosis (DVT) within the&#xD;
                  preceding 6 months;&#xD;
&#xD;
               -  congestive heart failure NYHA class III or IV;&#xD;
&#xD;
               -  active cancer within the last 5 years or a diagnosis of cancer within the last 5&#xD;
                  years (excluding basal cell carcinoma);&#xD;
&#xD;
               -  fibromyalgia, myopathy, rhabdomyolysis, unexplained muscle pain or weakness,&#xD;
                  and/or discontinuation of a statin because of myalgia; and/or&#xD;
&#xD;
               -  life expectancy &lt; 2 years.&#xD;
&#xD;
          7. Patient has any of the following abnormalities at any of the Screening or&#xD;
             Qualification Visits:&#xD;
&#xD;
               -  CPK elevation &gt; 3xULN;&#xD;
&#xD;
               -  aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 1.3xULN;&#xD;
&#xD;
               -  serum creatinine ≥ 1.5 mg/dL;&#xD;
&#xD;
               -  creatinine clearance &lt; 30 mL/min, as calculated using the Cockroft and Gault&#xD;
                  formula by the central laboratory;&#xD;
&#xD;
               -  active gout symptoms and/or uric acid level &gt; 1.3xULN;&#xD;
&#xD;
               -  and/or active peptic ulcer disease;&#xD;
&#xD;
          8. Patient is planning to undergo major surgery within the next 6 months;&#xD;
&#xD;
          9. Patient has any health condition or laboratory abnormality that, in the opinion of the&#xD;
             Principal Investigator, may be adversely affected by the procedures or medications in&#xD;
             this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>COMPELL TEAM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Contact COMPELL Team Member (800) 722-4567</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2006</verification_date>
  <study_first_submitted>March 10, 2004</study_first_submitted>
  <study_first_submitted_qc>March 11, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2004</study_first_posted>
  <last_update_submitted>October 31, 2006</last_update_submitted>
  <last_update_submitted_qc>October 31, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2006</last_update_posted>
  <keyword>Niaspan</keyword>
  <keyword>Niacin</keyword>
  <keyword>Statin</keyword>
  <keyword>Cholesterol</keyword>
  <keyword>Triglycerides</keyword>
  <keyword>Lipid-Modifying Therapies</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Coronary Heart Disease</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Stroke</keyword>
  <keyword>VA-HIT</keyword>
  <keyword>Niacin Statin Combination Threrapy</keyword>
  <keyword>High Density Lipoprotein</keyword>
  <keyword>Low Density Lipoprotein</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Adult Treatment Panel III</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

